Vanucizumab

Vanucizumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized
Target	angiopoietin 2
Clinical data
Other names	RG7221
ATC code	none;
Identifiers
CAS Number	1448221-05-3;
ChemSpider	none;
UNII	B800Z06O8K;
KEGG	D11244;
Chemical and physical data
Formula	C6529H10033N1733O2038S46
Molar mass	146887.94 g·mol−1

Vanucizumab (INN; development code RG7221) is an experimental humanized monoclonal antibody designed for the treatment of cancer.^[1]^[2]

Vanucizumab is a bi-specific monoclonal antibody composed of two different heavy chains and two different light chains. One arm of the antibody binds Angiopoietin-2 (Ang2) and the other is based on bevacizumab (Avastin), binding Vascular Endothelial Growth Factor A (VEGF-A). The antibody is designed to inhibit both VEGF-A and Ang2 simultaneously to offer superior clinical benefit compared to VEGF-A inhibition alone.

This drug was developed by Genentech/Roche.

References

↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.
↑ World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).

This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] Statement On A Nonproprietary Name Adopted By The USAN Council - Vanucizumab, American Medical Association.

[2] World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 111" (PDF). WHO Drug Information. 28 (2).

[1]

[2]